

In the Claims:

Please cancel claims 31, 33, 37-40, 43, 63, and 105 without prejudice to subsequent renewal.
Please amend the following claims by substituting the claims for the corresponding previously pending claims of the same number(s):

C6
32. (Amended) An isolated or recombinant polypeptide comprising a sequence selected from the group consisting of: SEQ ID NO:36 to SEQ ID NO:70 and SEQ ID NO:79 to SEQ ID NO:85.

C7
34. (Twice Amended) An isolated or recombinant polypeptide, comprising:
the amino acid sequence: CDLPQTHSLG-X₁₁-X₁₂-RA-X₁₅-X₁₆-LL-X₁₉-QM-X₂₂-R-X₂₄-S-X₂₆-FSCLKDR-X₃₄-DFG-X₃₈-P-X₄₀-EEFD-X₄₅-X₄₆-X₄₇-FQ-X₅₀-X₅₁-QAI-X₅₅-X₅₆-X₅₇-HE-X₆₀-X₆₁-QQTFN-X₆₇-FSTK-X₇₂-SS-X₇₅-X₇₆-W-X₇₈-X₇₉-X₈₀-LL-X₈₃-K-X₈₅-X₈₆-T-X₈₈-L-X₉₀-QQLN-X₉₅-LEACV-X₁₀₁-Q-X₁₀₃-V-X₁₀₅-X₁₀₆-X₁₀₇-X₁₀₈-TPLMN-X₁₁₄-D-X₁₁₆-ILAV-X₁₂₁-KY-X₁₂₄-QRITLYL-X₁₃₂-E-X₁₃₄-KYSPC-X₁₄₀-WEVVRAEIMRSFSFSTNLQKRLRRKE (SEQ ID NO:71), or a conservatively substituted variation thereof;

wherein X₁₁ is N or D; X₁₂ is R, S, or K; X₁₅ is L or M; X₁₆ is I, M, or V; X₁₉ is A or G; X₂₂ is G or R; X₂₄ is I or T; X₂₆ is P or H; X₃₄ is H, Y or Q; X₃₈ is F or L; X₄₀ is Q or R; X₄₅ is G or S; X₄₆ is N or H; X₄₇ is Q or R; X₅₀ is K or R; X₅₁ is A or T; X₅₅ is S or F; X₅₆ is V or A; X₅₇ is L or F; X₆₀ is M or I; X₆₁ is I or M; X₆₇ is L or F; X₇₂ is D or N; X₇₅ is A or V; X₇₆ is A or T; X₇₈ is E or D; X₇₉ is Q or E; X₈₀ is S, R, T, or N; X₈₃ is E or D; X₈₅ is F or L; X₈₆ is S; X₈₈ is E or G; X₉₀ is Y, H, N; X₉₅ is D, E, or N; X₁₀₁ is I, M, or V; X₁₀₃ is E or G; X₁₀₅ is G or W; X₁₀₆ is V or M; X₁₀₇ is E, G, or K; X₁₀₈ is E or G; X₁₁₄ is V, E, or G; X₁₁₆ is S or P; X₁₂₁ is K or R; X₁₂₄ is F or L; X₁₃₂ is T, I, or M; X₁₃₄ is K or R; and X₁₄₀ is A or S.

C8
41. (Amended) An isolated or recombinant polypeptide, comprising:
an amino acid sequence comprising at least 50 contiguous amino acids of any one of SEQ ID NOS:36-70, the amino acid sequence comprising one or more of amino acids Ala19, (Tyr or

C8
Gln)34, Gly37, Phe38, Lys71, Ala76, Tyr90, Ile132, Arg134, Phe152, Lys160, and Glu166, wherein the numbering of the amino acids corresponds to that of SEQ ID NO:36, which polypeptide exhibits an antiproliferative activity in a human Daudi cell line-based cell proliferation assay or an antiviral activity in a human WISH cell/EMCV-based assay.

C9
51. (Amended) An isolated or recombinant polypeptide comprising an amino acid sequence comprising at least 155 contiguous amino acids of any one of SEQ ID NOS:36-70, the isolated or recombinant polypeptide comprising amino acids Lys160 and Glu166, wherein the numbering of the amino acids corresponds to that of SEQ ID NO:36, which polypeptide exhibits an antiproliferative activity in a human Daudi cell line-based cell proliferation assay or an antiviral activity in a human WISH cell/EMCV-based assay.

C10
54. (Amended) The polypeptide of claim 32, 34, 41, or 51, further comprising a secretion/localization sequence.

C11
55. (Amended) The polypeptide of claim 32, 34, 41, or 51, further comprising a polypeptide purification subsequence.

C12
57. (Amended) The polypeptide of claim 32, 34, 41, or 51, further comprising a Met at the N-terminus.

58. (Amended) The polypeptide of claim 32, 34, 41, or 51, comprising a modified amino acid.

60. (Amended) A composition comprising the polypeptide of claim 32, 34, 41, or 51 and an excipient.

C13 62. (Amended) A composition comprising the polypeptide of claim 58 and a pharmaceutically acceptable excipient.

C14 120. (Amended) The polypeptide of claim 32, 34, 41, or 51, said polypeptide having an increased growth inhibition activity against a population of cancer cells relative to the inhibition activity of human interferon-alpha 2a against the population of cancer cells.

C15 124. (Amended) The polypeptide of claim 149, further comprising a secretion/localization sequence.

125. (Amended) The polypeptide of claim 149, further comprising a polypeptide purification subsequence.

127. (Amended) The polypeptide of claim 149, further comprising a Met at the N-terminus.

C16 128. (Amended) The polypeptide of claim 149, comprising a modified amino acid.

C17 130. (Amended) A composition comprising the polypeptide of claim 149, and an excipient.

C18 132. (Amended) A composition comprising the polypeptide of claim 128 and a pharmaceutically acceptable excipient.

C19 147. (Amended) The polypeptide of claim 149, said polypeptide having an increased growth inhibition activity against a population of cancer cells relative to the inhibition activity of human interferon-alpha 2a against the population of cancer cells.